Jetema the toxin 100U, which has been approved for export botulinum toxin, will conduct phase 3 clinical trials in Korea.

The MFDS recently approved Jetema the toxin for a "multi-organization, double-blind, random assignment, parallel design, noninferiority trials, active control groups, and phase 3 clinical trials" for JTM201. The clinical trial will be conducted at Asan Medical Center in Seoul, Konkuk University Hospital, and Chung-Ang University Hospital.

Jetema is conducting a clinical trial of Jetema the toxin after obtaining a drug manufacturing license in January 2019, and is expected to officially apply for an item license in Korea when the phase 3 clinical trial is completed.